Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average) (2015 - 2026)

Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 12 years deep, the most recent figure standing at $90.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 24.78% year-over-year to $90.0 million; the TTM figure through Mar 2026 stood at $90.0 million (up 24.78% YoY), while the FY2025 annual figure was $79.0 million, up 29.48% from the prior year.
• Shares Outstanding (Weighted Average) was $90.0 million for Q1 2026 at Corvus Pharmaceuticals, up from $79.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $90.0 million in Q1 2026 to a low of $46.6 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $58.6 million across 5 years, with a median of $49.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) gained 0.01% in 2023, then soared 47.08% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $46.6 million in 2022, then climbed by 3.16% to $48.0 million in 2023, then advanced by 26.99% to $61.0 million in 2024, then rose by 29.48% to $79.0 million in 2025, then rose by 13.97% to $90.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $90.0 million (Q1 2026), $79.0 million (Q4 2025), and $77.6 million (Q3 2025), per Business Quant data.